Eisai’s 2008 Eribulin NDA Plan Foiled; Beat To The Punch By BMS Drug
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA has dealt a setback to Eisai's burgeoning oncology pipeline by denying the company's efforts to seek accelerated approval for its microtubule growth suppressor E7389 (eribulin mesylate)